ASCO 2022 Updates in HR+/HER2- eBC
Lecture Summary - ASCO 2022 Adjuvant Abemaciclib for High-risk Early Breast Cancer: Factors Increasing the Rate of Treatment Discontinuations in monarchE
By
ASCO 2022 Conference Coverage
FEATURING
Sara Tolaney
By
ASCO 2022 Conference Coverage
FEATURING
Sara Tolaney
Login to view comments.
Click here to Login
ASCO 2022 Updates in HR+/HER2- eBC